Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 8/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 6/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20418044 | 1.00 | PTPN11 (0.47) | PTPN11HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL20417882 | 0.90 | PTPN11 (0.43) | PTPN11HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL25365596 | 0.89 | PTPN11 (0.52) | PTPN11HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL23126468 | 0.87 | PTPN11 (0.51) | PTPN11HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL30809730 | 0.87 | PTPN11 (0.51) | PTPN11HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL30561183 | 0.86 | PTPN11 (0.59) | PTPN11HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL30594000 | 0.86 | PTPN11 (0.59) | PTPN11HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL20399797 | 0.86 | PTPN11 (0.59) | PTPN11HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL22389873 | 0.84 | PTPN11 (0.51) | PTPN11 | |
| SCHEMBL29771167 | 0.84 | PTPN11 (0.51) | PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3571199-B1 | BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | REVOLUTION MEDICINES INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260103469-A1 | BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | REVOLUTION MEDICINES INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12365688-B2 | Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2025-07-22 | — | — | US | disclosed |
| US-20240199616-A1 | BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-06-20 | — | — | US | disclosed |
| US-11739093-B2 | Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199616-A1 | BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | PTPN18, PTPN1, PTPN2 | PTPN11 12/4885HDAC3 1112/4885HDAC4 1838/4885 |
| US-12365688-B2 | Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors | PTPN5, PTPN2, PTPN1 | PTPN11 13/4885HDAC3 1008/4885HDAC4 1182/4885 |
| US-20260103469-A1 | BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | PTPN5, PTPN6, PTPN1 | PTPN11 9/4885HDAC3 226/4885HDAC4 1131/4885 |
| US-11739093-B2 | Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors | PTPN5, PTPN2, PTPN4 | PTPN11 9/4885HDAC3 1008/4885HDAC4 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.